Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $500,100.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew L. Posard sold 10,000 shares of the stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 109,755 shares of the company’s stock, valued at $5,488,847.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $49.50 on Friday. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The stock has a 50 day moving average price of $42.82 and a 200 day moving average price of $39.66. The stock has a market capitalization of $6.30 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 52 week low of $32.83 and a 52 week high of $53.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. Analysts predict that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HALO. Rise Advisors LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at about $25,000. Whittier Trust Co. acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $27,000. Principal Securities Inc. acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $34,000. Fidelis Capital Partners LLC bought a new stake in Halozyme Therapeutics in the 1st quarter valued at $52,000. Finally, First Horizon Advisors Inc. lifted its holdings in Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on HALO shares. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $48.00 to $51.00 in a report on Friday, June 7th. TD Cowen started coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. Finally, JMP Securities decreased their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.13.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.